Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical passes the values gate
Price69.06 USD
Fair value58.17
Ethical score70.0/100
Our investment reviews on this name
2026-07-02Read Markup64.98+6.3% to today ✓
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Ashland Inc. holds its Markdown at $69.06. The statistical read favours the sellers, held for 26 days.
As held on the ledger · 2026-09-21
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 26 days
Price at the screen
$69.06
Valuation
44.27 trailing · 16.06 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.39
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
32.31%
Below 33%
Interest-bearing debt is just 32.3% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
9.91%
Below 49%
Money owed to the company is 9.9% of assets, under the 49% limit.
Pass
Revenue purity
0.27%
Below 5%
Only 0.3% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-21 screen. The gold marker is the market price at the same screen. The price runs 15.8% above the base estimate.
Third-party analyst targets: 11 covering, consensus Buy. The average target sits +16% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-21 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Chemicals maker priced for recovery that numbers reject
Picture a supplier of additives whose products end up in medicines and creams yet whose own books show deep red ink. Ashland trades well above our calculated worth with a negative margin of safety, and the bare facts give no reason to step in. Revenue barely moves while profits and returns sit deep in the red, so the current price simply does not match the business on show.
The forward multiple sits at sixteen times but offers no bargain once the cyclical trap is considered. Peak earnings often arrive just before the next downturn in specialty chemicals, and here earnings have already collapsed. Analyst targets sit higher yet rest on hopes rather than the delivered results of one percent growth and sharply negative returns on equity.
Currency swings, raw-material costs and demand drops in construction and consumer goods all sit ready to widen the gap between price and value. The ethical screen clears, yet that alone cannot rescue weak fundamentals. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ASH trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-22Markup$76.45+11.4%Entry 6
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 11.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 25%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (11 analysts) rates it buy, with a mean price target of $64.
2026-07-21Markup$68.64+5.6%Entry 5
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 5.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 25%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (11 analysts) rates it buy, with a mean price target of $64.
2026-07-18Markup$64.98+0.0%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 25%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (11 analysts) rates it buy, with a mean price target of $64.
2026-07-17Markup$64.98+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 25%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (11 analysts) rates it buy, with a mean price target of $64.
2026-07-03Markup$64.98+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Markup$64.98Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
